Current Market Outlook

Prediction markets on Kalshi give MDMA-assisted PTSD therapy a 54% chance of FDA approval before 2032. That is not a coin flip. It is a market that sees the outcome as genuinely uncertain, with neither side having a clear edge. The price has been stuck near 50% for months, reflecting deep division among traders about how the FDA will handle the first psychedelic-assisted therapy to reach its door.

Key Factors Driving the Odds

The FDA’s August 2024 rejection of Lykos Therapeutics’ application is the single biggest reason this market is not higher. The agency cited concerns about trial design, including functional unblinding (patients knew they got MDMA) and potential data integrity issues. The Complete Response Letter demanded a new Phase 3 trial, which would take years.

But the market is not at zero. Why? Because the FDA’s rejection was not a categorical no. The agency acknowledged the unmet need for PTSD treatments and left the door open for a resubmission. Lykos has since restructured its leadership, hired new regulatory consultants, and begun designing a trial that addresses the FDA’s specific criticisms. The 54% price reflects a bet that Lykos can fix the problems within five years.

The political climate also matters. The 2024 election brought a Republican administration that has signaled openness to psychedelic therapies. Trump’s FDA commissioner pick, Dr. Marty Makary, has written favorably about MDMA’s potential. But bureaucratic timelines are slow. Even with political will, a new trial takes 18-24 months to enroll, plus analysis and review time.

What Could Change These Odds

The next major catalyst is Lykos’s planned meeting with the FDA in mid-2025 to discuss the new trial design. If the agency signals agreement on endpoints and protocol, the market could jump to 70% or higher. If the FDA demands a larger or more complex trial, the probability could drop below 40%.

A competing approach could also shift odds. Several other companies are running MDMA trials with different protocols. If one of them shows stronger results or gets breakthrough therapy designation, the market would reassess the regulatory pathway.

The most likely scenario: approval before 2032, but not before 2027. The market is pricing in roughly even odds of success, which aligns with the historical rate of Phase 3 drugs getting FDA approval (about 50-60% for psychiatric drugs). The real question is whether Lykos can execute a clean trial this time.